Physician profile
Andrew Chapman
NPI 1306913033
$17,265.84
in general payments reported to CMS, 2019-2025
12 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $4,110 · 2021: $4,400 · 2022: $5,612 · 2023: $2,598 · 2024: $122 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $830 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $830.42 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Molecular Systems, INC. | $8,600.00 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $4,153.25 | 2020-2025 | Enhertu |
| Adc Therapeutics America, INC. | $3,000.00 | 2021 | |
| Spinal Simplicity, LLC | $412.30 | 2022 | |
| Aveo Pharmaceuticals, INC. | $238.18 | 2023 | Fotivda |
| Roche Diagnostics Corporation | $225.56 | 2019-2023 | |
| Ge Healthcare | $219.40 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $132.56 | 2023 | |
| Tempus Ai, INC | $122.32 | 2024 | Xt Cdx |
| Foundation Medicine, INC. | $100.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.27 | 2019 | |
| Kite Pharma, INC. | $25.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.